Mariann Ohanesian
Senior Director of Investor Relations
Replay available
Puma Biotechnology Inc (NASDAQ: PBYI) Q2 2026 earnings conference call, held 2026-08-06. Replay captured from the company's public earnings webcast.

Senior Director of Investor Relations
Chief Executive Officer, President and Chairman of the Board
Senior Vice President of Marketing
Senior Vice President of Sales
Chief Financial Officer
Analyst, TD Cowan
Good afternoon, my name is Darrell and I will be your conference call operator today. At this time, all participants are in a listen-only mode. After the speaker's formal remarks, there will be a question and answer session. If you would like to ask a question during that time, simply press the star key, then the number 1 on your telephone keypad. If you would like to withdraw your questions, please press star 2. If you should require operator assistance during the conference, please press star 0. As a reminder, this call is being recorded. I would now like to turn the conference call over to Mariann Ohanesian, Senior Director of IR for PUMA Biotechnology. You may begin your conference. Thank you, Darrell. Good afternoon and welcome to PUMA's conference call to discuss our earnings results for the second quarter of 2026. Joining me on the call today are Alan Auerbach, Chief Executive Officer, President and Chairman of the Board of PUMA Biotechnology, Maximo Nougues, Chief Financial Officer, Heather Blaber, Senior Vice President of Marketing, and Roger Storms, Senior Vice President of Sales. After the close today, PUMA issued a news release detailing earnings results for the second quarter of 2026. That news release, the slides that Roger will refer to, and a webcast of this call are accessible via the homepage and investor sections of our website at Pumatechnology.com. The webcast and presentation slides will be archived on our website and available for replay for the next 90 days. Today's conference call will include statements about Plumas' future expectations, plans, and prospects that constitute forward-looking statements for purposes of federal securities laws. Such statements are subject to risks and uncertainties, and actual events and results may differ from ...